Shared Decision Making to Improve Care and Outcomes for Children With Autism
NCT01921244 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142
Last updated 2016-02-05
Summary
Children with Autism Spectrum Disorder (ASD) commonly experience behavioral challenges that may be improved with pharmacotherapy, including difficulties with sleep, attention, hyperactivity, impulsivity, anxiety, obsessive-compulsive behavior, mood swings, self-injury, and aggression. While 34-58% of children with ASD take medication for such behaviors, there is wide practice variation nationally and a lack of evidence to support the use of most commonly prescribed agents. Complex clinical situations such as this where there is no clear "best choice" regarding which behaviors to target and which medications to use lend themselves well to the use of a Shared Decision Making (SDM) tool to ensure that well-informed parent preferences shape every treatment plan.
The primary goal of this study is to modify a previously published decision aid about use of medication to manage challenging behaviors in children with autism to make it easy to implement in practice and then evaluate this version in terms of proximal decisional outcomes and parent/child outcomes 3 months later. Providers in a Developmental-Behavioral Pediatric clinic will be enrolled and randomly allocated to intervention or control (treatment as usual) groups. Initially, providers randomized to the intervention group will test and refine the modified intervention. Once the intervention is finalized, eligible patients of participating providers will be enrolled in the randomized controlled trial to test the efficacy of the intervention. Following the trial, control group providers will be crossed over and receive the intervention. Both proximal decisional outcomes (e.g. parent decisional conflict, provider amount of SDM, parent knowledge of treatment options) and outcomes 3 months later (e.g. parenting stress, decisional conflict, and change in child behavioral symptoms) will be assessed.
Approximately 10 providers and 240 of their patients with autism will be included in the study. Chart reviews, parental surveys, and recordings of provider-parent-patient interactions during the index visit will be collected at baseline (prior to physician allocation), during the intervention trial, and after the control group has crossed over. Between- and within-group analyses will examine factors associated with parental decisional conflict and whether the intervention produces significant improvements in outcomes over and above typical autism care. Analyses will include multiple linear regression modeling and general linear models / repeated measure models, accounting for data clustered by provider.
Conditions
- Autistic Disorder
- Pervasive Developmental Disorder
- Child Development Disorders, Pervasive
- Asperger Syndrome
- Autism Spectrum Disorder
- Autism
Interventions
- OTHER
-
Decision Aid
Parents will receive an intervention modified from the previously published tool called "Autism: Should My Child Take Medicine for Challenging Behavior?" This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters.
Sponsors & Collaborators
-
Children's Hospital Medical Center, Cincinnati
lead OTHER
Principal Investigators
-
Julia Anixt, MD · Children's Hospital Medical Center, Cincinnati
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 4 Years
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2015-07-31
- Completion
- 2015-07-31
Countries
- United States
Study Locations
More Related Trials
-
Daily Living Skills Intervention for Adolescents With Autism Spectrum Disorder
NCT03984487 ·Status: COMPLETED ·Phase: NA
-
Community-Engaged Sleep Intervention for School-Aged Children With Autism Spectrum Disorder
NCT07007819 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
NCT01178385 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Deep Brain Stimulation for Severe Self-Injurious Behaviour in Children
NCT06529380 ·Status: RECRUITING ·Phase: NA
-
Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder
NCT03865719 ·Status: COMPLETED ·Phase: NA
-
Measurement of Treatment Effects
NCT07024303 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
NCT00873509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intranasal Oxytocin Treatment for Social Deficits in Children With Autism
NCT01624194 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Study of Fluoxetine in Children and Adolescents With Autism
NCT00004486 ·Status: COMPLETED ·Phase: NA
-
Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT03757585 ·Status: COMPLETED ·Phase: PHASE4
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
NCT02028247 ·Status: COMPLETED ·Phase: NA
-
Executive Function Intervention for High School Students With ASD
NCT03199937 ·Status: COMPLETED ·Phase: NA
-
Social and Communication Outcomes for Young Children With Autism
NCT00953095 ·Status: COMPLETED ·Phase: NA
-
Identification of Characteristics Associated With Symptom Remission in Autism
NCT00938054 ·Status: COMPLETED
-
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01302964 ·Status: COMPLETED ·Phase: PHASE3
-
Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety
NCT01919970 ·Status: COMPLETED ·Phase: NA
-
Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium
NCT02094651 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
NCT03664232 ·Status: COMPLETED ·Phase: PHASE2
-
Telephone Care Management to Address Sleep Problems in Young Children With Autism
NCT01558180 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD)
NCT04369417 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders
NCT00600470 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response
NCT02871349 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Optimizing Outcomes for Young Autistic Children
NCT05926687 ·Status: RECRUITING ·Phase: PHASE2
-
Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders
NCT02586935 ·Status: COMPLETED ·Phase: PHASE2
-
DOD Regulating Together Intervention
NCT05803369 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA